Business

Larimar Therapeutics to Participate in Upcoming Investor Conferences in March

BALA CYNWYD, Pa., March 04, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company’s management team will present and participate in 1x1 investor meetings at the following upcoming investor conferences taking place in Miami Beach, FL. Presentation details can be found below. Leerink Partners Global Healthcare ConferenceDate: Tuesday

articleLarimar Therapeutics, Inc.March 4, 20261/company/larimar-therapeutics-inc/news/larimar-therapeutics-to-participate-in-upcoming-investor-conferences-in-march-120
Larimar Therapeutics to Participate in Upcoming Investor Conferences in March

About this update from Larimar Therapeutics, Inc.

[{"type":"image","alt":"Larimar Therapeutics","displaySize":"","headline":null,"caption":"Larimar Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":107,"url":"https://media.zenfs.com/en/globenewswire.com/59a0cb6afa06818e6bf352c70da11d95"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1uUrf9fLQ_8GcyV6eEAsEw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/59a0cb6afa06818e6bf352c70da11d95","width":300,"height":107}},"lazy":false},{"type":"text","content":"BALA CYNWYD, Pa., March 04, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company’s management team will present and participate in 1x1 investor meetings at the following upcoming investor conferences taking place in Miami Beach, FL.","length":400,"tagName":"p"},{"type":"text","content":"Presentation details can be found below.","length":40,"tagName":"p"},{"type":"text","content":"Leerink Partners Global Healthcare ConferenceDate: Tuesday, March 10, 2026Time: 8:40 AM ETWebcast Link:https://event.summitcast.com/view/mT9poctHDNthc6b89WqVjf/FAcSQYGbUgaSReiyPwMwXA","length":186,"tagName":"p"},{"type":"text","content":"The Citizens Life Sciences ConferenceDate: Wednesday, March 11, 2026Time: 4:00 PM ETWebcast Link:https://event.summitcast.com/view/BuMiPNPtyHKimMF6k4AFMd/U4zRP6eBjWF5GAvrtX3HAZ","length":180,"tagName":"p"},{"type":"text","content":"Following the conclusion of the presentations, a replay will be available for 30 days on the “Events and Presentations” page of Larimar’s website.","length":146,"tagName":"p"},{"type":"text","content":"About Larimar TherapeuticsLarimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.","length":553,"tagName":"p"},{"type":"text","content":"Investo...

More updates from Larimar Therapeutics, Inc.

rare diseasesbiotechnology companyNasdaqLarimar Therapeutics, Inc.Larimar TherapeuticsGlobal Healthcare ConferenceLarimar